Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Agent for improving or preventing progression of chronic kidney disease

A chronic kidney disease and improver technology, applied in the direction of medical preparations containing active ingredients, pill delivery, organic active ingredients, etc., can solve the problems of no comparison of drug efficacy, no further development, and the effect cannot be said to be significant, etc., to achieve Easy to take, high safety effect

Inactive Publication Date: 2016-10-12
NIPPON ZOKI PHARM CO LTD
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] (2) Glomerular filtration rate (GFR) decreased to less than 60mL / min / 1.73m 2
However, there is no comparison of the efficacy of the compound for the development of the patient's condition
In addition, the effect of the present compound shown by these clinical test results cannot be said to be significant, and the development of the present compound has not been further developed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for improving or preventing progression of chronic kidney disease
  • Agent for improving or preventing progression of chronic kidney disease
  • Agent for improving or preventing progression of chronic kidney disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0045] Next, the results of clinical trials using this drug (dosage form is a tablet) are shown. First, as a reference example, the results of a clinical test conducted before are illustrated, and next, as an example, the results of a clinical test conducted recently are illustrated to specifically explain the meaning of the present invention, but the present invention is not limited thereto.

[0046] Reference example Clinical trial results (1)

[0047] Clinical trials shown in Non-Patent Documents 1 and 2 will be described. Non-Patent Document 2 is a continuation report of the clinical trial of Non-Patent Document 1. The clinical trials involved in these two documents are referred to as "old clinical trials" below.

[0048] In the previous clinical trial, the test drug was orally administered once a day for 24 weeks to patients with diabetic CRF, and the efficacy and safety of this compound were evaluated. The test subjects were patients receiving conservative therapy for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to provide a drug which is administered to patients suffering from chronic kidney disease that involves rapid progression of kidney dysfunction, in order to improve, or prevent the progression of, the disease state. The present invention relates to an agent for improving or preventing the progression of chronic kidney disease, the agent containing as the active ingredient 5-hydroxy-1-methyl hydantoin. This drug has exhibited a remarkable effect in patients suffering from chronic kidney disease that involves rapid progression of kidney dysfunction. This drug is extremely useful as a highly safe drug for improving, or preventing progression of, kidney dysfunction in patients suffering from rapidly progressing chronic kidney disease for which there have thus far been no effective therapeutic drugs that could be easily taken.

Description

technical field [0001] The present invention relates to compounds containing 5-hydroxy-1-methylhydantoin (IUPAC name: 5-hydroxy-1-methylimidazolidine-2,4-dione) (hereinafter sometimes referred to as "this compound") as The active ingredient is an agent for inhibiting or improving the development of chronic kidney disease. Background technique [0002] Chronic kidney disease (CKD: chronic kidney disease) is a relatively new disease concept proposed by the American Kidney Foundation (NKF) in 2002. The causes include various systemic diseases and kidney diseases, and diabetes, hypertension, chronic nephritis and the like are representative. CKD was defined as either (1) or (2) below or both persisting for more than 3 months. [0003] (1) Kidney disease, especially proteinuria of 0.15 g / gCr or more (albuminuria of 30 g / gCr or more) is known by urinalysis, imaging / pathological diagnosis, blood test, etc. (The unit " / gCr" means "per 1g of creatinine".) [0004] (2) Glomerular ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4166A61K9/20A61P13/12
CPCA61K9/2013A61K9/2054A61K9/2853A61K9/2866A61K31/4166A61P13/12A61K9/0053A61K9/2009A61K9/2813
Inventor 家永和治
Owner NIPPON ZOKI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com